Understanding Individual SARS-CoV-2 Proteins for Targeted Drug Development against COVID-19 | Zendy

Joyce van de Leemput | Zendy; Zhe Han | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Understanding Individual SARS-CoV-2 Proteins for Targeted Drug Development against COVID-19

Author(s) -

Joyce van de Leemput,

Zhe Han

Publication year - 2021

Publication title -

molecular and cellular biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.14

H-Index - 327

eISSN - 1067-8824

pISSN - 0270-7306

DOI - 10.1128/mcb.00185-21

Subject(s) - biology , coronavirus , pandemic , outbreak , virus , virology , drug development , covid-19 , viral entry , population , viral replication , computational biology , drug , medicine , infectious disease (medical specialty) , disease , pharmacology , environmental health , pathology

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the COVID-19 pandemic, responsible for millions of deaths globally. Even with effective vaccines, SARS-CoV-2 will likely maintain a hold in the human population through gaps in efficacy and vaccination and arising new strains.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research